Technical Analysis for PBYI - Puma Biotechnology Inc

Grade Last Price % Change Price Change
grade F 6.5 -2.69% -0.18
PBYI closed down 2.69 percent on Friday, October 18, 2019, on 1.15 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Oct 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical PBYI trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -2.69%
Narrow Range Bar Range Contraction -2.69%
NR7 Range Contraction -2.69%
New 52 Week Low Weakness -2.69%

Older signals for PBYI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Chemistry Cancer Chemical Compounds Organic Compounds Non Small Cell Lung Cancer Chloroarenes Pyridines Tyrosine Kinase Receptors Protein Kinase Inhibitor Epidermal Growth Factor Receptor Aromatic Amines Her2/Neu Advanced Breast Cancer Nitriles Treatment Of Advanced Breast Cancer Treatment Of Various Forms Of Cancer
Is PBYI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 43.9
52 Week Low 6.475
Average Volume 1,556,780
200-Day Moving Average 20.3814
50-Day Moving Average 10.2053
20-Day Moving Average 9.1308
10-Day Moving Average 7.348
Average True Range 0.6471
ADX 36.34
+DI 9.922
-DI 37.1422
Chandelier Exit (Long, 3 ATRs ) 10.3787
Chandelier Exit (Short, 3 ATRs ) 8.4163
Upper Bollinger Band 13.1372
Lower Bollinger Band 5.1244
Percent B (%b) 0.17
BandWidth 87.755728
MACD Line -1.1898
MACD Signal Line -0.9026
MACD Histogram -0.2872
Fundamentals Value
Market Cap 241.84 Million
Num Shares 37.2 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -0.80
Price-to-Sales 0.00
Price-to-Book 37.58
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.85
Resistance 3 (R3) 6.88 6.79 6.79
Resistance 2 (R2) 6.79 6.70 6.78 6.77
Resistance 1 (R1) 6.65 6.65 6.60 6.62 6.75
Pivot Point 6.56 6.56 6.54 6.55 6.56
Support 1 (S1) 6.42 6.47 6.37 6.39 6.25
Support 2 (S2) 6.33 6.42 6.32 6.23
Support 3 (S3) 6.19 6.33 6.21
Support 4 (S4) 6.16